| 000 | 03426cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223031856.0 | ||
| 008 | 171212s2017 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aM.Sc | ||
| 099 | _aCai01.19.04.M.Sc.2017.Mo.N | ||
| 100 | 0 | _aMohamed Tarek Hamed Shouman | |
| 245 | 1 | 0 |
_aNon-endometrioid malignant tumors of the uterine corpus : _bClinicopathological results and treatment outcomes at NCI / _cMohamed Tarek Hamed Shouman ; Supervised Amany Mohamed Helal , Eman Loay Hussien , Alfred Elias Namour |
| 246 | 1 | 5 |
_aالأورام الخبيثة بالرحم الغير شبيهة ببطانة الرحم : _bالنتائج الاكلينيكية والمرضيه ونتائج العلاج بالمعهد القومى للأورام |
| 260 |
_aCairo : _bMohamed Tarek Hamed Shouman , _c2017 |
||
| 300 |
_a143 P. : _bcharts , facsimiles ; _c25cm |
||
| 502 | _aThesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Oncology (Medical) | ||
| 520 | _aBackground: Uterine corpus cancer is the most common gynecological malignancy in developed countries and the second most common after cancer cervix in developing countries. Non-Endometrioid malignancies have higher risks for recurrence and distant metastasis that may address the need for adjuvant therapy. Ways to improve treatment results needs a better assessment of different prognostic factors to find the best treatment modality. Objective: The aim of this retrospective study is to identify the clinic-pathological data, prognostic factors and different treatment modality results which affect diseasefree survival (DFS) and overall survival (OS) of Non-endometrioid malignancies of the uterine corpus. Patients and methods: All patients{u201F} files presented to NCI in the period between January 2009 to December 2013 having Non-Endometrioid malignancy of uterine corpus were retrieved and reviewed. Results and conclusions: The most frequently encountered pathology was carcinosarcoma for Nonendometrioid carcinoma accounting for 48.7% and Leiomyosarcoma for uterine sarcoma accounting for 46.7%. Patients most frequently presented with stage I disease. The most dominant site of metastasis on follow up was the lung. The most VII frequently used treatment modality for Non-endometrioid carcinoma was surgery alone (35%), while (23.6%) of the studied patients underwent surgery followed by EBRT in which (25.7%) received Brachytherapy after EBRT, (22.3%) of patients underwent surgery followed by EBRT and chemotherapy and (14.4%) underwent surgery followed by chemotherapy. While for uterine sarcoma, the most common treatment modality was surgery alone (73.3%), while (16.6%) of the studied patients underwent surgery followed by EBRT in which (33.3%) received Brachytherapy after EBRT, (3.3%) of patients underwent surgery followed by EBRT and chemotherapy and (6.6%) underwent surgery followed by chemotherapy | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aNon-Endometrioid carcinoma | |
| 653 | 4 | _aRadiotherapy | |
| 653 | 4 | _aUterine sarcoma | |
| 700 | 0 |
_aAlfred Elias Namour , _eSupervisor |
|
| 700 | 0 |
_aAmany Mohamed Helal , _eSupervisor |
|
| 700 | 0 |
_aEman Loay Hussien , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aShimaa _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c64001 _d64001 |
||